UWM
BLRX

Urban Wealth Management’s BioLineRX BLRX Stock Holding History

Urban Wealth Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$12K Buy
+229
New +$12.7K 0.04% 188

Other funds holding BLRX

PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Urban Wealth Management's BLRX Position: Q2 2022 in Review

Urban Wealth Management opened a new position in BioLineRX (BLRX) in Q2 2022: 229 shares worth $12K. The stake represents 0.04% of the portfolio and ranks #188 among its holdings.

28 funds tracked by Wall St. Rank hold BLRX as of Q2 2022.

  • Urban Wealth Management held 229 shares of BioLineRX worth $12K as of Q2 2022.
  • BioLineRX was a new Urban Wealth Management position in Q2 2022.
  • BioLineRX made up 0.04% of Urban Wealth Management's portfolio in Q2 2022, its #188 holding.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.